Study guide

5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days)

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days)

Key Takeaways Explain This Topic AI

Category 3 CSPs may be dated beyond Category 2 limits, up to 60 days at room temperature, 90 days refrigerated and 120 days frozen if aseptically processed, or 90/120/180 days if terminally sterilized.

Every Category 3 batch must be sterility tested (USP <71> or a validated alternative), and any batch that requires sterility testing is capped at 250 final yield units.

The BUD must be supported by stability data from a stability-indicating method for the exact formulation and container-closure materials. Published or unpublished studies qualify only if they match exactly.

Category 3 compounders repeat garbing and aseptic manipulation competencies at least every 3 months.

A Category 3 facility also needs sterile low-lint outer garb with no exposed skin, monthly air sampling, weekly surface sampling (plus the PEC after each batch), and weekly sporicidal disinfection.

Last updated: September 2026

The Category 3 High-Reliability Compounding Tier

In specialized health-system pharmacies, home infusion establishments, and ophthalmology compounding practices, clinical necessity often demands beyond-use dates that exceed the standard Category 2 default thresholds (for example, a 60-day refrigerated BUD for batch-prepared syringes or bags used in home infusion or ophthalmology).

To assign these extended dates, USP General Chapter <797> establishes the Category 3 CSP tier . Category 3 is not an architectural classification, but a comprehensive, intensified quality assurance regime that validates both chemical stability and continuous sterility assurance over long storage durations.

Maximum Allowable Category 3 BUD Limits

Compounding & Sterilization Method Controlled Room Temp ( 20 ∘ C 20^\circ\text{C} 2 0 ∘ C to 25 ∘ C 25^\circ\text{C} 2 5 ∘ C ) Refrigerated ( 2 ∘ C 2^\circ\text{C} 2 ∘ C to 8 ∘ C 8^\circ\text{C} 8 ∘ C ) Frozen ( − 25 ∘ C -25^\circ\text{C} − 2 5 ∘ C to − 10 ∘ C -10^\circ\text{C} − 1 0 ∘ C )

  • Aseptically processed CSP Up to 60 days Up to 90 days Up to 120 days
  • Terminally sterilized CSP Up to 90 days Up to 120 days Up to 180 days

Warning

These timeframes represent absolute compendial ceilings. Under no circumstances may a facility assign a BUD exceeding 120 days for an aseptically processed CSP or 180 days for a terminally sterilized CSP, even if chemical stability data exists for 1 year.

Mandatory Prerequisites for Category 3 Compounding

To assign a Category 3 BUD, a facility must meet every requirement in USP <797> Section 14.4 at all times , not just on the days it makes Category 3 CSPs (USP FAQ):

Cleanroom Suite Required : Category 3 CSPs are made in an ISO Class 5 PEC in an ISO Class 7 buffer room with an anteroom, or in a pharmaceutical isolator in an ISO Class 8 or better room. They can never be made in a Segregated Compounding Area (SCA).

Batch Sterility Testing : Every Category 3 batch must be sterility tested per USP <71>, by membrane filtration or direct inoculation, or by a validated alternative that is non-inferior (USP <1223>). Batches are capped at 250 final yield units. If a CSP is dispensed before results are known, the notification and recall procedures in USP <797> 18.1 must be ready.

Bacterial Endotoxin Testing : Injectable Category 3 CSPs made from any nonsterile component must pass bacterial endotoxin testing (USP <85>).

Stability Data : The facility must have stability data from a validated stability-indicating method, such as HPLC that separates intact drug from its degradation products. The study must use the exact formulation (ingredients of identical grade and procedure) and container-closure materials, and it may be published or unpublished. It does not need to be repeated for each batch.

Environmental Monitoring and Cleaning : Viable air sampling within 30 days before starting and then monthly; surface sampling weekly, plus inside the PEC after each batch; a sporicidal disinfectant applied at least weekly.

Quarterly Personnel Qualification : Category 3 compounders repeat the garbing competency and the aseptic manipulation competency (media fill, gloved fingertip sample and direct compounding area surface sample) at least every 3 months .

Sterile Garbing with No Exposed Skin : All low-lint outer garb in the Category 3 buffer room is sterile, and the face and neck are covered. Goggles and respirators need not be sterile but must be disinfected per SOP.

Analytical Stability Testing: Stability-Indicating Assays (SIA) & Forced Degradation

USP <797> requires Category 3 BUDs to rest on a stability-indicating analytical method . The method must distinguish the active ingredient from its degradants and impurities, for example as shown by forced degradation studies, and it must quantify the drug. It is validated using characteristics such as those in USP <1225>. The facility must keep documentation of the study: methodology, method validation and all results. Extrapolation, or a method such as simple UV absorbance that cannot tell drug from degradant, does not qualify.

Chromatographic Separation : An SIA (typically HPLC-DAD or LC-MS/MS) physically separates the intact parent drug molecule from all degradation products, excipients, and impurities.

Forced Degradation (Stress Testing) : Typical laboratory practice stresses the drug with acid, base, oxidation, heat and light. The goal is to show that the degradation products separate from the parent peak, with adequate resolution and peak purity.

Container-Closure Integrity Testing (CCIT) Methodologies

A preparation stored for up to 120 or 180 days depends on its seal the whole time. USP <1207> describes container closure integrity (CCI) testing. USP <797> requires CCI evaluation for multiple-dose CSP containers, and USP's FAQ lists closure integrity among factors to weigh when assigning long BUDs. It is not, however, a separately listed Category 3 release test. The methods in USP <1207> include:

Deterministic CCIT Methods : USP <1207> favors deterministic, non-destructive quantitative testing over legacy dye ingress.

High-Voltage Leak Detection (HVLD) : Detects micro-cracks and pinholes down to sub-micron dimensions ( < 1 μ m < 1\,\mu\text{m} < 1 μ m ) in liquid-filled parenteral vials.

Vacuum Decay Testing (ASTM F2338) : Hermetically evacuates a test chamber and measures pressure rise from escaping vapor, detecting leaks down to 1 to 2 μ m 1\text{ to }2\,\mu\text{m} 1 to 2 μ m .

Frequency Modulation Spectroscopy (FMS) : Laser-based headspace gas analysis measuring oxygen or carbon dioxide ingress over time.

Release Testing for Category 3 Batches

Test USP <797> status for Category 3 Key facts

Visual inspection (<797> 12.1) Required for every CSP Particulates, discoloration, container closure defects, label match

Sterility (USP <71>) Required for every batch 14 days in Fluid Thioglycollate Medium and Soybean-Casein Digest Medium, or a validated alternative; batch 250 units maximum

Bacterial endotoxins (USP <85>) Required for injectables with any nonsterile component Limit = K M = \frac{K}{M} = M K ​ ; K = 5.0 EU/kg K = 5.0\,\text{EU/kg} K = 5.0 EU/kg parenteral, 0.2 EU/kg 0.2\,\text{EU/kg} 0.2 EU/kg intrathecal

Subvisible particulates (USP <788>) Not a listed <797> release test Large-volume (> 100 mL): ≤ 25 \le 25 ≤ 25 /mL ≥ 10 μ m \ge 10\,\mu\text{m} ≥ 10 μ m and ≤ 3 \le 3 ≤ 3 /mL ≥ 25 μ m \ge 25\,\mu\text{m} ≥ 25 μ m ; small-volume: ≤ 6,000 \le 6{,}000 ≤ 6 , 000 and ≤ 600 \le 600 ≤ 600 per container

Potency assay Not a listed per-batch <797> test (the stability study supports the BUD) Many facilities test potency anyway as a quality control